DexCom, Zynex, Olin And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Portfolio Pulse from Avi Kapoor
Several major stocks, including DexCom, Zynex, Olin, and others, are experiencing significant declines in Friday's pre-market session. DexCom's shares fell sharply due to worse-than-expected Q2 revenue and weak FY24 guidance. Other companies like Zynex, Ur-Energy, Tandem Diabetes Care, MacroGenics, Olin Corporation, Carter’s, and Indivior also saw declines due to various financial results and announcements.
July 26, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Carter’s shares fell 7.4% in pre-market trading following weak quarterly sales.
Weak quarterly sales are likely to result in a negative short-term impact on Carter’s stock price.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 100
NEGATIVE IMPACT
DexCom's shares fell 37% in pre-market trading after reporting worse-than-expected Q2 revenue and issuing weak FY24 guidance.
DexCom's significant revenue miss and weak future guidance are likely to negatively impact investor sentiment, leading to a sharp decline in stock price.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100
NEGATIVE IMPACT
Indivior shares fell 4.4% in pre-market trading after a 20% jump on Thursday following better-than-expected Q2 results and a $100 million share repurchase program.
The decline may be a correction following the previous day's significant gains, reflecting short-term volatility.
CONFIDENCE 75
IMPORTANCE 50
RELEVANCE 100
NEGATIVE IMPACT
MacroGenics shares dipped 8.9% in pre-market trading after gaining 5% on Thursday.
The decline may be a correction following the previous day's gains, reflecting short-term volatility.
CONFIDENCE 75
IMPORTANCE 50
RELEVANCE 100
NEGATIVE IMPACT
Olin Corporation shares declined 8.1% in pre-market trading following a second-quarter earnings miss.
Olin's Q2 earnings miss is likely to negatively impact investor sentiment, leading to a decline in stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Tandem Diabetes Care shares declined 9% in pre-market trading ahead of its Q2 earnings release.
Investor uncertainty ahead of the Q2 earnings release is likely causing the decline in Tandem Diabetes Care's stock price.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 100
NEGATIVE IMPACT
Ur-Energy shares fell 9.2% in pre-market trading after announcing a proposed public offering of common shares.
The announcement of a public offering typically dilutes existing shares, leading to a negative impact on the stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Zynex shares declined 21.5% in pre-market trading after reporting worse-than-expected Q2 financial results.
Zynex's poor Q2 financial performance is likely to result in a negative short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100